Achieving the unimaginable: Health equity in haemophilia

Historically, treatment based on the availability of clotting factor replacement has resulted in an arcane guideline for the correction of factor deficiencies in people with haemophilia (PwH). While all other disease entities seek to restore function to a normal level, PwH are restricted to factor nadirs still equivalent to mild or moderate disease, resulting in continued risk of bleeding. A new treatment paradigm is needed based on the defined needs of PwH. A treatment model was developed by a panel of haemophilia providers, patient advocates and health economists to establish specific treatment milestones and targeted outcomes. The panel defined a series of treatment milestones to characterize the activity and outcomes linked to level of factor deficiency correction. All agreed that the ultimate goal should be ‘functional cure’ and ‘health equity’. Seven levels to achieving a functional cure were identified, (a) Sustain life; (b) Minimal joint impairment; (c) Freedom from any spontaneous bleeds; (d) Attainment of ‘normal’ mobility; (e) Able to sustain minor trauma without additional intervention; (f) Ability to sustain major surgery or trauma; and (g) Normal haemostasis. A parallel set of patient‐reported outcomes to achieve health equity was identified. These guidelines are now comparable with other disorders where the goal is to replace missing proteins to attain normal activity levels. As we are no longer limited by plasma supply due to the manufacture of recombinant factors, mimetics, and the early success of gene therapy, health equity is now achievable.

[1]  C. Goodman,et al.  Patient‐centred value framework for haemophilia , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  G F Pierce,et al.  Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. O’Hara,et al.  The impact of severe haemophilia and the presence of target joints on health-related quality-of-life , 2018, Health and Quality of Life Outcomes.

[4]  C. Peterfy,et al.  Effect of late prophylaxis in hemophilia on joint status: a randomized trial , 2017, Journal of thrombosis and haemostasis : JTH.

[5]  G. Auerswald,et al.  Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment , 2017, British journal of haematology.

[6]  E. Andersson,et al.  Preference‐based valuation of treatment attributes in haemophilia A using web survey , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  P. McLaughlin,et al.  Study of physical function in adolescents with haemophilia: The SO‐FIT study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Astermark,et al.  Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  M. Nijziel,et al.  Mortality caused by intracranial bleeding in non‐severe hemophilia A patients , 2017, Journal of thrombosis and haemostasis : JTH.

[10]  A. Iorio,et al.  Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Gill,et al.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. , 2017, Blood.

[12]  David B Clark,et al.  Impact of mild to severe hemophilia on engagement in recreational activities by US men, women, and children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B‐HERO‐S) study , 2017, European journal of haematology.

[13]  O. Stasyshyn,et al.  Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  B. Kerlin,et al.  Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A‐LONG and Kids A‐LONG Studies , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  K. Wyrwich,et al.  Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐LONG and B‐LONG clinical studies , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  M. Carcao,et al.  An institutional pilot study to investigate physical activity patterns in boys with haemophilia , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  H. Schünemann,et al.  NHF‐McMaster Guideline on Care Models for Haemophilia Management , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  B. Riske,et al.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database. , 2016, Blood.

[19]  M. Nichol,et al.  Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status , 2015, American journal of hematology.

[20]  D. Cooper,et al.  Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study , 2015, Patient preference and adherence.

[21]  C. Witmer,et al.  Organized sports participation and the association with injury in paediatric patients with haemophilia , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  C. Santoro,et al.  Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study , 2015, Thrombosis and Haemostasis.

[23]  J. Oldenburg Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. , 2015, Blood.

[24]  J. Mahlangu,et al.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) , 2015, Journal of thrombosis and haemostasis : JTH.

[25]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[26]  A. Iorio,et al.  Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  C. Kempton,et al.  Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.

[28]  M. Salvatore,et al.  Magnetic resonance imaging and ultrasound evaluation of “healthy” joints in young subjects with severe haemophilia A , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  J. Gill,et al.  The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia , 2013, British journal of haematology.

[30]  S. Israels,et al.  Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study , 2013, Journal of thrombosis and haemostasis : JTH.

[31]  J. P. Dijk,et al.  A survey of the outcome of prophylaxis, on‐demand treatment or combined treatment in 18–35‐year old men with severe haemophilia in six countries , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  P. Monagle,et al.  Association between physical activity and risk of bleeding in children with hemophilia. , 2012, JAMA.

[34]  M. Skinner WFH: Closing the global gap – achieving optimal care , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  K. Kurnik,et al.  Identification and long‐term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[37]  T. Takken,et al.  Habitual physical activity in Dutch children and adolescents with haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[39]  M. Cerinic,et al.  Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  C. Manno,et al.  Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States , 2011, British journal of haematology.

[41]  M. Porter,et al.  What is value in health care? , 2010, The New England journal of medicine.

[42]  J. Astermark,et al.  Physical activity for prevention of osteoporosis in patients with severe haemophilia on long‐term prophylaxis , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  Z. Dvir,et al.  Physical activity participation and bleeding characteristics in young patients with severe haemophilia , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  J. Oldenburg,et al.  Haemophilia care then, now and in the future , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[45]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[46]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[47]  B. Evatt Observations from Global Survey 2001: an emerging database for progress , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  J. Mchardy,et al.  Twice weekly prophylactic therapy in haemophilia A. , 1977, Journal of clinical pathology.

[49]  Å. Ahlberg Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.